Clinical trials: Nocturia
Nocturia
Daytime Impact Sleep Study
This trial will investigate the relationship of sleep, daytime performance and nocturia in patients treated with Desmopressin or placebo.
- Trial name
- DAISS (NCT01779466)
- Testing
- Desmopressin
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study
The primary objectives of the study are: To determine the absolute bioavailability of SK-1404 To assess the mass balance recovery after a single oral (PO) dose of carbon-14 (14C)-SK-1404 To provide plasma, urine and faecal…
- Trial name
- NCT02878096
- Testing
- [14C]-SK-1404
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Bladder Function
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
This is an observational, pilot, non-treatment study to evaluate and develop clinical variables for distinguishing female OAB subjects that have detrusor overactivity positive (DO+) nocturia from female OAB subjects that have…
- Trial name
- NCT01099345
- Testing
- cystometry (CMG), polysomnography (PSG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Inc
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00615836
- Testing
- Desmopressin Melt
- Where
- 73 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia Due to Nocturnal Polyuria
Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
The purpose of this trial is to demonstrate efficacy of SK-1404 against placebo for the treatment of subjects with nocturia due to nocturnal polyuria, during 4 weeks of treatment.
- Trial name
- NCT03116191
- Testing
- SK-1404
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Urinary Incontinence, Urinary Incontinence, Urge
Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)
UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature…
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Fecal Incontinence, Fecal Incontinence With Fecal Urgency
- Trial name
- NCT06091566
- Testing
- UCon-Bar
- Where
- 3 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Nocturia
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients.
- Trial name
- NOC (NCT01184859)
- Testing
- Desmopressin
- Where
- 36 sites in Japan
- Volunteers
- 116 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Nocturia
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of male subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.
- Trial name
- NCT02904759
- Testing
- Desmopressin
- Where
- Japan
- Volunteers
- 342 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in…
- Trial name
- NCT03201419
- Testing
- FE 201836, Desmopressin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 302 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Dose Range Finding Study of Fedovapagon in Men With Nocturia
The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
- Trial name
- NCT01656239
- Testing
- fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg
- Where
- 56 sites in United States
- Volunteers
- 358 people
- Sponsor
- Vantia Ltd
Nocturia
Treatment of Patients With Nocturia
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937859
- Testing
- SER120
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Overactive Bladder
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of…
- Trial name
- NCT01729819
- Testing
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Nocturia
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with…
- Trial name
- COMFORT (NCT01223937)
- Testing
- Desmopressin
- Where
- 45 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Ferring Pharmaceuticals
Nocturnal Polyuria
A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US
To estimate the prevalence of nocturia due to nocturnal polyuria (NP) in the US and describe the demographic and clinical characteristics as well as the burden of illness in participants with nocturia due to NP.
- Trial name
- NCT04125186
- Testing
- Baseline EpiNP survey, Bladder diary, Testing of EpiNP baseline survey, bladder diary and a qualitative interview
- Where
- United States
- Volunteers
- 10,190 people
- Sponsor
- Ferring Pharmaceuticals